Výsledky vyhledávání - "Shiloh M. Martin"

B cell reductive therapy in the treatment of autoimmune diseases: A focus on monoclonal antibody treatment of rheumatoid arthritis

Autor: Kyle R. Song, Shiloh M. Martin, Theodore Wun, Joseph Tuscano

Publikováno v: Hematology. 10:521-527

The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recogniz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb0c4c5df73ccdbdaa363f00fb266515
https://doi.org/10.1080/10245330500155424

Zobrazit plný text záznamu

B-cell lymphoma line (Raji) viability and surface marker expression minimally affected by 20- and 25-gauge vitrectomy systems analyzed by flow cytometry

Autor: David G. Telander, Shiloh M. Martin, Denis M. Dwyre, Sara P. Modjtahedi, Cecilia Yeung, Rupan Trikha

Publikováno v: Retina (Philadelphia, Pa.). 30(9)

The purpose of this study was to evaluate the effect of 20-gauge (20-G) and 25-gauge (25-G) vitrectomy on cell viability and diagnostic yield (surface marker expression) using flow cytometry and human lymphoma cells in culture.Cultured human Burkitt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6372e8d8ea2d77f812c6312579ebf18f
https://pubmed.ncbi.nlm.nih.gov/20829744

Zobrazit plný text záznamu

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

Autor: Shiloh M. Martin, Joseph Tuscano, William C. Zamboni, Yunpeng Ma, Robert T. O'Donnell

Publikováno v: O’Donnell, Robert T.; Martin, Shiloh M.; Ma, Yunpeng; Zamboni, William C.; & Tuscano, Joseph M.(2010). Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Investigational New Drugs: The Journal of New Anticancer Agents, 28(3), pp 260-267. doi: 10.1007/s10637-009-9243-7. Retrieved from: http://www.escholarship.org/uc/item/19v2201f
Investigational New Drugs

Summary Non-Hodgkin’s lymphoma (NHL) is the sixth most common cause of cancer deaths in the U.S. Most NHLs initially respond well to chemotherapy, but relapse is common and treatment is often limited due to the toxicity of chemotherapeutic agents.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e60a277d2146b9a4c59e79be9bacdb
http://www.escholarship.org/uc/item/19v2201f

Zobrazit plný text záznamu

Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model

Autor: Yunpeng Ma, Robert T. O'Donnell, William C. Zamboni, Shiloh M. Martin, Joseph Tuscano

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 16(10)

Purpose: Non–Hodgkin's lymphoma (NHL) is the sixth most common cause of cancer death in the U.S. Pegylated liposomal doxorubicin (PLD) is a liposomal form of doxorubicin (DXR) that causes less toxicity than does free DXR. To further enhance efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1834de8edca9c764f47074b88f7548eb
https://pubmed.ncbi.nlm.nih.gov/20460479

Zobrazit plný text záznamu

Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts

Autor: David L. Kukis, Craig K. Abbey, Joseph Tuscano, Shiloh M. Martin, Robert T. O'Donnell, Julie L. Sutcliffe, Hayes McKnight

Publikováno v: Molecular imaging and biology. 11(2)

The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of (64)Cu-DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ).Mice bearing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e0052679217218d16372f5c23344d65
https://pubmed.ncbi.nlm.nih.gov/18949521

Zobrazit plný text záznamu

The Bispecific Anti-CD20/CD22 Antibody (Bs20x22) Has More Lymphomacidal Activity Than the Parent Antibodies Both Alone or In Combination

Autor: Yunpeng Ma, Shiloh M. Martin, Robert T. O'Donnell, Joseph Tuscano, Laura Newell

Publikováno v: Blood. 116:425-425

Abstract 425 Background: Over 400,000 people in the United States are living with non-Hodgkin's lymphoma (NHL). While survival rates have improved, over 20,000 persons die annually from NHL. Cytotoxic chemotherapies are initially effective, but resis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e3dd04444c96649e82a060f671c2c8c
https://doi.org/10.1182/blood.v116.21.425.425

Zobrazit plný text záznamu

Intravenous, Intraperitoneal, and Subcutaneous Routes of Administering 64Cu-DOTA-HB22.7 Display Equivalent Tumor Targeting Ability

Autor: Julie L. Sutcliff, Shiloh M. Martin, Joseph Tuscano, Robert T. O'Donnell, Hayes McKnight

Publikováno v: Blood. 110:2359-2359

BACKGROUND: Chemotherapy for Non-Hodgkin’s Lymphoma (NHL) is initially effective, but often limited by toxicity and resistance. New agents for the treatment of NHL are needed. HB22.7 is a monoclonal antibody that binds CD22 and has previously been

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6a0fb580584f7e573e57670152a760d
https://doi.org/10.1182/blood.v110.11.2359.2359

Zobrazit plný text záznamu

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

Autor: Yunpeng Ma, Shiloh M. Martin, Hayes McKnight, Robert T. O'Donnell, Christopher M. Mahaffey, Eric Churchill, Joseph Tuscano

Publikováno v: Journal of Hematology & Oncology
Martin, Shiloh M; Churchill, Eric; McKnight, Hayes; Mahaffey, Christopher M; Ma, Yunpeng; O'Donnell, Robert T; et al.(2011). The HB22.7 Anti-CD22 Monoclonal Antibody Enhances Bortezomib-mediated Lymphomacidal Activity in a Sequence Dependent Manner. Journal of Hematology & Oncology, 4(1), 49. doi: http://dx.doi.org/10.1186/1756-8722-4-49. Retrieved from: http://www.escholarship.org/uc/item/2k29s3d3
Journal of Hematology & Oncology, Vol 4, Iss 1, p 49 (2011)

Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibitor with anti-NHL activity; it is currentl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40a1309f5321ae1379db66a7e0493d16

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání